Synthesis of the first phosphorus (V) porphyrin-peptide conjugate was successfully accomplished. A biologically active peptide, leucine enkephalin, was constructed on the phosphorus atom of the 5,10,15,20-meso-tetraphenylporphinato dichlorophosphorus (V) chloride. The method involved solution phase peptide synthesis. The first C-terminal amino acid in the sequence of the peptide was axially attached to the porphyrin through a linker, 3-aminopropanol, and the remainder of leucine enkephalin was synthesized by subsequent additions of amino acids. Leucine enkephalin -P(V) porphyrin conjugate represents a new group of compounds, and its synthesis broadens potential applications of P(V) porphyrins, e.g. in photodynamic therapy.
Introduction
Free base, meso-substituted porphyrins attract more attention than any other subclass of porphyrinic compounds [1] [2] . However, phosphorus (V) porphyrins are of significant interest due to their broad potential applications. They are used for DNA sequence sensing, to construct molecular photoswitches, and as models in photochemistry [3] [4] [5] [6] [7] [8] . Phosphorus (V) porphyrins have been investigated as photosensitizers in DNA binding/cleaving processes due to their strong oxidizing power in the singlet and triplet excited states and their ability to generate singlet oxygen. Because they are promising synthetic photonucleases, they offer potential applications in cancer chemotherapy and molecular biology. The possibility of stable axial derivatization broadens the usefulness of those compounds [9] .
The chemistry of peptide P(V) porphyrins is unknown. To the best of our knowledge, there are no known compounds that represent such a class of conjugates. In this paper, the chemistry, design and synthesis of peptide P(V) porphyrins were investigated. When covalently attached, peptides could increase the target specificity and therefore usefulness of the P(V) porphyrins. The idea is very promising because of the virtually unlimited applications of peptides or proteins.
In this paper, the synthetic efforts were focused on diaxial derivatization of the P(V) porphyrin's center with leucine enkephalin (Leu-enkephalin), a naturally occurring pentapeptide. Enkephalins are opioid receptor agonists; they are peptides that, among other purposes, are responsible for decreasing sensation of pain [10] . The proenkephalin, enkephalin precursor or polymeric molecule consisting of as many as 267 enkephalin units, is synthesized in mammal brains. Whenever there is a need for the enkephalin monomers, a carboxypeptidase and a trypsin-like enzyme cut them out of the precursor [11] . There are two known types of enkephalins: leucine and methionine (Met-enkephalin) [12] . Their sequences are as follows: Tyr-Gly-Gly-Phe-Leu and Tyr-Gly-Gly-Phe-Met, respectively. The structure of Leu-enkephalin is given in Fig. 1 . The methionine derivative is approximately 30-fold more potent, or has a 30-fold higher affinity to the opioid receptor, than the analogous leucine form. In nature, there are approximately four molecules of Met-enkephalin per molecule of Leu-enkephalin [13] . Because of its interesting biological properties, enkephalin was chosen here as the axial ligand of the first peptide-P(V) porphyrin. A linker was attached to enkephalin's C-terminal amino acid, leucine, followed by the conjugation of such a fragment with the porphyrin. Tyrosine's hydroxyl group could technically serve as the linking moiety as well, however in such a case, biological activity of the peptide would have been lost. The attachment of the linker was the only structural modification of enkephalin. In future research, this might be a very important point in a case where the peptide's biological activity is to be retained. The C-terminus → N-terminus elongation of the peptide chain was attempted due to the known, convenient chemistry of peptide synthesis with utilization of N-hydroxysuccinimide (HO-Su) ester / tert-butyloxycarbonyl (t-BOC) protected amino acids. Due to its stability, 5,10,15,20-meso-tetraphenyl porphyrin was a convenient porphyrin compound for the first conjugation with a peptide. The method that involves direct conjugation of a presynthesized peptide with the porphyrin was rejected due to previous failures in attempting to directly attach a shorter peptide (Thr-Tyr-Ser) to the P(V) porphyrin. Since P(V) porphyrins can survive the acidic conditions during deprotection (specifically, removal of the t-BOC groups), step-by-step synthesis of the peptide on the porphyrin through the addition of subsequent amino acids was performed. The new P(V) porphyrin was characterized and its properties described.
Experimental

Materials
Pyridine, ethyl acetate, sodium sulfate, n-hexane, tetrahydrofuran (THF), acetonitrile, trifluoroacetic acid (TFA) -Fisher, phosphorus oxychloride, methanol, ethanol, chloroform, methylene chloride, 5,10,15,20-meso-tetraphenylporphyrin (TPP), trimethylsilyl cyanide (TMSCN), tert-butyloxycarbonyl-leucine hydroxysuccinimide ester (t−BOC-Leu-OSu), tert-butyloxycarbonyl-phenylalanine hydroxysuccinimide ester (t−BOC-Phe-OSu), tert-butyloxycarbonyl-glycine hydroxysuccinimide ester (t−BOC-Gly-OSu), tertbutyloxycarbonyl-tyrosine hydroxysuccinimide ester (t−BOC-Tyr-OSu), threonyltyrosinyl-serine (Thr-Tyr-Ser) -Fluka, 3-amino-1-propanol (3APOL), butyronitrile (dried over molecular sieves), TLC plates SiO 2 60 on Al -Aldrich, deuterated chloroform -Isotec INC.
Instruments and Methods
UV-Vis spectra were recorded with a diode array spectrophotometer, Ocean Optics, INC. ES-MS spectra were recorded with a Quattro II, Micromass Electrospray System. Solutions were delivered into the MS source at a flow rate of 10 µL/min using a syringe pump (Harvard Apparatus). A potential of 2.5-3 kV was applied to the electrospray needle and a potential of 150 V was applied to the ion source. All MS spectra were an average of 10 scans over a range of 400 to 2000 m/z. MassLynx V3.5 software was used to collect and analyze MS data. NMR spectra were recorded with a Bruker Avance 500 and a Bruker AC 300.
Syntheses of Semiproducts
5,10,15,20-meso-Tetraphenylporphinato dichlorophosphorus (V) chloride [TPP-P(V)-Cl 2 ]
+ Cl − , the starting material, was obtained from 5,10,15,20-tetraphenylporphyrin and phosphorus oxychloride according to the improved method of Carrano [14] . Yield: 95 %.
tert-Butyloxycarbonyl-leucine-3-hydroxypropanamide (t−BOC-Leu-3APOL) was synthesized by means of improved solution phase peptide synthesis [15] , utilizing N-protected active ester and trimethylsilyl cyanide (TMSCN) as a supporting reagent.
3APOL (0.4 g) was dissolved in TMSCN (0.4 g). The solution was protected from moisture and stirred for 2 hours. After that time, a solution of t−BOC-Leu-OSu (0.8 g) in 10 mL of dry THF was added dropwise. The mixture was protected from moisture and stirred for 24 hours. Water (30 mL) was added to quench the reaction and after 5 minutes of stirring, THF was evaporated under reduced pressure. The post-reaction mixture was extracted three times with 20 mL portions of methylene chloride, the combined extracts dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The crude product was chromatographed on silica with CHCl 3 /AcOEt/MeOH 6:2:1, which yielded pure, by TLC and ES-MS, product as a yellowish, oily residue (300 mg 
Syntheses of the P(V) porphyrins 2.4.1 Conjugation, general procedure
The two reagents were dissolved in dry butyronitrile. The mixture was protected from moisture and refluxed or stirred at room temperature. The removal of the solvent under reduced pressure yielded a crude product that was dissolved in chloroform and purified twice, with Chromatotron, on silica. This was followed by a separation on a preparative plate (same mobile phase; silica), which gave a pure product, by TLC and ES-MS. The product was immediately deprotected; the t-BOC groups were removed from both amino termini of the axial substituents. The details are given in section 2.4.3.
Deprotection, general procedure
The entire amount of product obtained from the conjugation step was dissolved in methylene chloride, followed by a dropwise addition of trifluoroacetic acid, with magnetic stirring at room temperature. When the diprotected and monodeprotected compounds were gone (monitored by TLC), the solvent and excess of TFA were evaporated under reduced pressure. The product was purified with a Chromatotron, on silica. A single run was sufficient to obtain pure compound, which in turn was used in the next step:
attachment of the next amino acid in the sequence (conjugation). The details are given in section 2.4.3.
Synthetic details
Besides the starting material, [TPP-P(V)- 
Results and discussion
In the first synthetic step, 3-aminopropanol (3APOL, the linker) was attached to leucine, the first C-terminal amino acid in the sequence of Leu-enkephalin. Then, in the next step, the conjugation of the derivatized leucine with the phosphorus atom of the porphyrin was achieved. The deprotection of N-termini of both axial substituents exposed the amino groups for the following step in the synthesis, which was addition of the next amino acid, phenylalanine. The twelve-step synthesis of the title compound was successfully accomplished by this addition-deprotection method. The structure of the new P(V) porphyrin is given in Fig. 3 . The P(V) porphyrin diaxially substituted with leucine enkephalin was synthesized. The method involving solution phase peptide synthesis seems to be a convenient way to obtain peptide derivatized P(V) porphyrins. Conjugation of the entirely pre-synthesized peptide with a P(V) porphyrin might be an alternative route. However, the conjugation yields decrease extremely rapidly with increasing size of the molecule to be axially linked to the P(V) center of the porphyrin. The increasing size of a peptide is commonly associated with decreasing solubility in organic solvents, which makes the choice of the solvent problematic. The longer the peptide, the harder it is to choose a suitable solvent for both reagents in the final conjugation step.
Direct attachment of a shorter peptide to the P(V) porphyrin was attempted in order to check the possibility of such one-step conjugation of the two units. The sequence of the tripeptide was Thr-Tyr-Ser. All of the amino acids in the sequence contained hydroxyl groups that could potentially react with the phosphorus (V) porphyrin. In the first attempt, the conjugation was carried out in butyronitrile, which is a common solvent for reactions of P(V) porphyrins. The tripeptide was not soluble in that solvent, however, and the conjugation of the reagents in suspension was attempted. Twenty-four hour reflux yielded a mixture that was analyzed by ES-MS, which did not detect even trace amounts of the expected product (expected m/z = 1408, C 78 H 76 N 10 O 14 P). The reaction was repeated two more times using acetonitrile and pyridine as the solvents. Despite excellent solubility of the tripeptide and [Cl 2 P(V)TPP] + Cl − in both solvents, ES-MS again did not detect any amounts of the expected product. It is possible that the unprotected peptide termini interfered with the synthesis. However, if either terminus displayed any affinity toward the P(V) center of the porphyrin, the presence of the product with the same m/z ratio should have been detected using ES-MS, and this was not the case. Polymeric molecules were not detected either. The main reaction that occurred was a thermal decomposition of the starting material, indicated by formation of the free base TPP. This suggested the superiority of the step-by-step method, despite its limitations; its low yield in particular (0.52 % total yield). Certain problems with separation associated with the presence of both hydrophilic and hydrophobic groups in the molecule (loss of material on the stationary phase due to the "permanent" adsorption), together with repeated separations after every step of the reaction, significantly decreased the overall yield. However, this drawback was compensated by improved control over the reaction. The possible isolation of monodeprotected products (that could be used for asymmetric axial substitution) following relatively simple synthetic steps made this method more desirable than the aforementioned direct conjugation technique. It is worthwhile to mention that another technique might combine the advantages of the two described methods, while eliminating their disadvantages. The axial peptides do not have to be synthesized from single amino acids, which is a pathway that is severely limited by the size of the desired substituent. The synthesis of a large peptide might proceed through subsequent additions of oligopeptide units. This approach has the potential to reduce the problem of low yields while keeping the synthesis possible.
Increasing the size of the peptide chain was associated with improving water solubility of the porphyrins. After attachment of the third amino acid (glycine), the porphyrin derivative became soluble in water. The subsequent additions of the amino acids further improved its solubility. This might be a key property of related compounds, allowing for their bioapplications; usually, solubility in water is necessary for a drug candidate to work.
ES-MS was used to characterize the (Leu-enkephalin-3APOL) 2 P(V)TPP. The porphyrin fragmented in a characteristic way; its fragmentation pattern was analogous to similar P(V) porphyrins described elsewhere [16] [17] . The ES-MS spectrum of the (Leu-enkephalin-3APOL) 2 P(V)TPP is illustrated in Fig. 4 . In the first step of fragmentation (Leu-enkephalin-3APOL) 2 P(V)TPP lost one of the axial substituents as an alkyl group; the R-OP bond broke. The M + -R was seen at m/z = 1275. The loss of another axial substituent, also as an alkyl, resulted in the dihydroxy derivative at m/z = 677, which further decomposed (eliminated water), yielding a porphyrin centrally substituted with P=O at m/z = 659. Since M + and all of the aforementioned fragments could further decompose to free base TPP (phosphorus atom leaves the central cavity), its relative abundance was significant; m/z = 615. The evidence collected from the ES-MS experiments suggested that the bonds connecting the axial oxygen atoms with the remaining part of the axial substituents (R-OPO-R) were the weakest in the molecule, followed by the P-O bond and the bonds linking phosphorus atom with the pyrrole nitrogen atoms.
Conclusions
The first peptide-P(V) porphyrin conjugate has been successfully synthesized. The synthesis proves that the step-by-step construction of axial peptide substituents on the P(V) center is possible, and opens the way to a new class of P(V) porphyrins. The new compound, (Leu-enkephalin-3APOL) 2 P(V)TPP, is soluble in water, which is an important property when considering its (or its analogues') potential pharmaceutical applications. Regardless of particular applications for such conjugates, the presence of a peptide in the molecule may allow for a more specialized mode of action. The appropriate choice of axial peptide substituents might solve problems that limit the applications of P(V) porphyrins. For instance, increasing the selective affinity for the target molecules through proper substituent selection could improve drug delivery (e.g. in photodynamic therapy). The obtained peptide-P(V) porphyrin is stable and further elongation of the peptide chain is possible. Isolation of the monodeprotected products allows for asymmetric substitution of the two axial positions (e.g. utilizing solid phase synthesis). The weakest and therefore least stable bonds in the molecule are those that link the axial substituents with the central phosphorus-oxygen group (PO-R), as demonstrated by ES-MS. The step-by-step synthetic method proves to be more useful than direct conjugation of the pre-synthesized axial substituent with the porphyrin. However, problems associated with separation of the semiproducts and the resulting low yields are the drawbacks of the former. Synthesis of the axial peptides from oligopeptide units as opposed to synthesis from amino acids might prove to be the best approach.
